Guest Column

New shot at life for Africa’s babies

2017-05-14 11:37
Syringe with vaccination

Syringe with vaccination (iStock)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Keith Klugman

As Africa gathered at the beginning of May for the World Economic Forum on Africa, there were many successes to celebrate.

There was also a need to discuss plans to mitigate challenges we expect the continent to face in the coming decade.

It was inspiring to see so many great minds come together behind a common goal, and fascinating to hear about the different ways people propose to overcome the hurdles ahead.

But my favourite bit of news from the week is something you may have missed.

On May 2, South African manufacturer Biovac Institute announced – with Path, an international health organisation – that it had joined forces to develop a new vaccine for Group B Streptococcus (GBS).

This project makes Biovac the first African company to attempt to develop a GBS vaccine specifically designed to protect mothers and babies in sub-Saharan countries where the disease is most prevalent.

A viable solution to prevent GBS – a bacterium carried by up to a third of adults, most commonly in the gut, and for up to 25% of women in the vagina, usually with no symptoms or side-effects – before babies are even born would be a huge boon to child health, not just in Africa, but in other regions of the world as well.

While GBS isn’t exactly a household name, it is one of the leading killers of newborns.

In some parts of the world, the mortality rate from GBS is as high as 38%, and in South Africa there are 2.38 cases of GBS per 1 000 live births.

Moreover, an estimated one in four pregnant women is a carrier of the GBS bacterium. Even babies who survive the illness can often be left with life-long disabilities.

Infant mortality, especially in sub-Saharan Africa, is nebulous and largely mysterious.

There’s still a lot we don’t know about why kids are dying. We’re lucky that, when it comes to GBS, we actually do know quite a bit.

For instance, we know approximately how many deaths are caused by GBS, and we know that it can infect children any time immediately after birth or in the first month of life.

This information, on its own, cannot stop deaths from GBS, but it can give us a pretty good idea of where to start to prevent it and what questions to ask.

We know, for instance, that giving antibiotics to mothers can prevent the onset of GBS for the baby during the newborn period.

But this method is not effective at protecting against GBS when the infant is slightly older.

Biovac’s proposed solution to this problem is a vaccine that would be given to pregnant women, who would then pass on the immunity to their children.

The early weeks of life are a crucial period when infants are unprotected.

It’s too early in a child’s life to administer vaccines directly, but too late for the protection of antibiotics given to the mother to be in effect.

We have seen vaccines for flu, for example, have protective effects using this same approach and are optimistic that we will see the same type of results for GBS.

Of course, ideas and projects as ambitious as this one don’t come overnight, and no one can come up with them alone.

The department of science and technology has been working to develop the infrastructure to host a vibrant research and innovation hub for decades now.

They recognised early on that innovation would be crucial to solving previously intractable problems such as this one for child health.

None of this would be possible without the resources and effort that have been dedicated to growing the country’s network of top-quality universities and an advanced cadre of researchers and entrepreneurs.

But even given that, developing and manufacturing vaccines is a hard, complicated business.

That’s why it’s so important, even for leading scientists, to partner with organisations that are already working on vaccines.

Biovac’s partner, Path, has one of the world’s largest vaccine-development portfolios, and expertise in the full range of research that will make this development possible.

In addition, Inventprise, a biotechnology start-up in Seattle, will provide technical support to this project in the early stages.

Inventprise has experience developing the kinds of vaccines that can pass from pregnant mothers to children, and its role will be to ensure that Biovac has all the resources it needs to develop the kind of vaccine it envisions – one that is specifically targeted to address GBS in sub-Saharan Africa and similar regions.

This partnership is the exact type of project the Bill & Melinda Gates Foundation likes to fund: one where babies’ lives are saved, the public and private sectors come together to solve an old problem in a new way, and where local expertise can shine.

We’re honoured to be able to support this project and can’t wait to see how many lives are saved because of it.

Klugman is director for pneumonia at the Bill & Melinda Gates Foundation.

Follow him on Twitter @findingpneumo

Read more on:    wef  |  vaccines

Rampaging through H&M

2018-01-17 12:16

Rampaging through H&M

2018-01-17 12:16


Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.